In recent years, with the promotion of the new medical reform policy, the domestic pharmaceutical industry has gradually upgraded from generic drugs to innovative drugs, and local pharmaceutical companies have accelerated the pace
of innovation and transformation.
At present, the competition for innovation of local pharmaceutical companies is not only in the product line, but also in the competition for talents
.
Recently, some media reported that Tao Weikang, who was the deputy general manager and R&D CEO of Hengrui, has joined Qilu Pharmaceutical as the vice president of the group and the general manager
of Qilu global innovative drug research and development.
It is understood that Tao Weikang will become an important member of the global innovative R&D system management team of Qilu Pharmaceutical Group, fully lead the research and development of Qilu's global innovative drugs, formulate and implement innovative drug R&D strategies, and participate in the planning and implementation
of the company's innovative drug R&D development strategy.
According to his resume, Tao Weikang has been engaged in new drug research and development at Merck for more than ten years, serving as a senior researcher and department head, and presided over the research and development and project management
of a number of new anti-cancer drugs.
During his tenure at Hengrui, he served as the company's deputy general manager of pharmaceuticals and CEO of the R&D center, and participated in the development of
PD-1.
Like Hengrui Pharmaceutical, Tao Weikang's new owner, Qilu Pharmaceutical, is in the transition stage
from generics to innovation.
At present, the company has more than 80 innovative drug projects under development, of which 13 Class 1 new drugs are in different clinical research stages, and more than 10 projects are located in the IND stage
.
In addition, Qilu Pharmaceutical's product line also has antibody drugs, as of March 2022, Qilu has disclosed 5 compound antibodies/bispecific antibodies, surpassing monoclonal antibodies, ADCs and fusion proteins, and 3 have entered the clinical stage
.
The industry believes that Qilu Pharmaceutical and Hengrui are both pharmaceutical companies of innovation and transformation, and behind the talent flow between the two, it can be seen that the competition for talents in the industry has intensified
.
From the perspective of the industry, with the explosive growth of the number of innovative pharmaceutical companies, the development prospects of the domestic innovative pharmaceutical industry are broad, but due to the late start in China, local pharmaceutical companies have an urgent demand for talents, and the current situation is that such talents are very lacking, and enterprises do not have much time for talent training and growth, resulting in the phenomenon
of competition between pharmaceutical companies for high-level talents with rich experience, especially those who have worked in multinational pharmaceutical companies.
Since the beginning of this year, many local innovative pharmaceutical companies have introduced new talents, especially talents
who have rich work experience in local pharmaceutical companies and multinational pharmaceutical companies.
For example, Luo Yongqing, former Executive Director, President and General Manager of Greater China, has joined Genting Sun Yao, a biopharmaceutical company focused on the development and commercialization of innovative drugs, to help the company continue to advance its late-stage product pipeline for commercialization, and will continue to invest in R&D platforms to build an innovative drug pipeline
。 It is reported that Luo Yongqing served as the global vice president and general manager of Gilead Sciences, and assisted Gilead Sciences in establishing its business in China, helping the clinical development, registration approval and successful marketing of 8 innovative products, including Sovaldi, Harvoni, Epclusa and TAF, with indications covering chronic hepatitis B, chronic hepatitis C and AIDS
.
For another example, Junshi Biologics' talent team has welcomed Zou Jianjun, who has nearly 30 years of rich experience in the fields of tumor clinical treatment, anti-tumor drug research and development and new drug clinical research, and has served as the head of medical affairs in China at Celgene Pharmaceutical, as well as the medical consultant and head of the therapeutic area of the China Oncology Department and the head of global medical affairs of Xofigo (US headquarters in New Jersey)
at Bayer Pharma.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
